1. Home
  2. KTF vs LYEL Comparison

KTF vs LYEL Comparison

Compare KTF & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DWS Municipal Income Trust

KTF

DWS Municipal Income Trust

BUY

Current Price

$8.04

Market Cap

361.2M

Sector

Finance

ML Signal

BUY

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$9.07

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTF
LYEL
Founded
1988
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
361.2M
320.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KTF
LYEL
Price
$8.04
$9.07
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $37.88
AVG Volume (30 Days)
★ 373.2K
122.8K
Earning Date
01-01-0001
11-11-2026
Dividend Yield
★ 3.54%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.39
N/A
Revenue
N/A
★ $36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.77
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.95
$9.36
52 Week High
$9.37
$45.00

Technical Indicators

Market Signals
Indicator
KTF
LYEL
Relative Strength Index (RSI) 25.77 23.04
Support Level N/A N/A
Resistance Level $9.26 $15.38
Average True Range (ATR) 0.09 0.53
MACD -0.02 -0.12
Stochastic Oscillator 13.21 10.46

Price Performance

Historical Comparison
KTF
LYEL

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: